Jiang G, Wu B, Wang K, Pu X, Zhou S, Zhong X
Eur J Med Res. 2025; 30(1):5.
PMID: 39754171
PMC: 11699706.
DOI: 10.1186/s40001-024-02177-9.
Li J, Wang X, Wang X, Liu Y, Zheng N, Xu P
Cancer Manag Res. 2022; 14:1551-1563.
PMID: 35502328
PMC: 9056025.
DOI: 10.2147/CMAR.S358963.
Abedi E, Karimi M, Yaghobi R, Mohammadi H, Haghpanah S, Moghadam M
J Clin Lab Anal. 2022; 36(4):e24289.
PMID: 35176183
PMC: 8993601.
DOI: 10.1002/jcla.24289.
Liang Z, Xie J, Huang L, Huang Y, Zhang Y, Ma R
J Gastrointest Oncol. 2021; 12(2):388-406.
PMID: 34012634
PMC: 8107618.
DOI: 10.21037/jgo-21-78.
Wu J, Li L, Wu S, Xu B
Cancer Biol Med. 2020; 17(3):528-542.
PMID: 32944388
PMC: 7476098.
DOI: 10.20892/j.issn.2095-3941.2020.0032.
CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells.
Yuan Y, Sheng Z, Liu Z, Zhang X, Xiao Y, Xie J
J Cancer. 2020; 11(13):3762-3770.
PMID: 32328181
PMC: 7171480.
DOI: 10.7150/jca.42314.
Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer.
Wu K, Li X, Gu H, Yang Q, Liu Y, Wang L
Int J Biol Sci. 2019; 15(12):2576-2583.
PMID: 31754330
PMC: 6854381.
DOI: 10.7150/ijbs.33733.
[Pathophysiologic mechanism of CMTM5 low expression in multiple myeloma progression].
Ma Y, Shi J, Qiu H, Yuan J, Zhang Y, Zhou P
Zhonghua Xue Ye Xue Za Zhi. 2019; 40(1):58-62.
PMID: 30704230
PMC: 7351701.
DOI: 10.3760/cma.j.issn.0253-2727.2019.01.011.
Up-regulation of miR-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5.
Guan L, Ji D, Liang N, Li S, Sun B
J Cell Mol Med. 2018; 22(7):3434-3441.
PMID: 29691981
PMC: 6010904.
DOI: 10.1111/jcmm.13620.
CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling.
Xu G, Dang C
Cancer Cell Int. 2017; 17:113.
PMID: 29213215
PMC: 5707824.
DOI: 10.1186/s12935-017-0485-8.
CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis.
Cai B, Xiao Y, Li Y, Zheng S
Oncol Lett. 2017; 14(2):1536-1542.
PMID: 28789377
PMC: 5529942.
DOI: 10.3892/ol.2017.6350.
CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
Xiao Y, Yuan Y, Zhang Y, Li J, Liu Z, Zhang X
Clin Transl Oncol. 2014; 17(6):431-7.
PMID: 25387568
DOI: 10.1007/s12094-014-1253-z.
CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis.
Li Z, Xie J, Wu J, Li W, Nie L, Sun X
PLoS One. 2014; 9(2):e88965.
PMID: 24586462
PMC: 3938458.
DOI: 10.1371/journal.pone.0088965.
The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma.
Zhang Y, Bao L, Lu J, Liu K, Li J, Qin Y
Mol Cancer. 2014; 13:25.
PMID: 24499297
PMC: 3922338.
DOI: 10.1186/1476-4598-13-25.
CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer.
Su Y, Lin Y, Zhang L, Liu B, Yuan W, Mo X
Cancer Sci. 2013; 105(1):26-34.
PMID: 24131472
PMC: 4317871.
DOI: 10.1111/cas.12304.
Evaluation of the Abelson gene as a control gene for real-time quantitative PCR in multiple myeloma.
Zhang Y, Ruan G
Clin Exp Med. 2013; 14(4):457-60.
PMID: 23990051
DOI: 10.1007/s10238-013-0257-2.
Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.
Singh S, Dev A, Verma R, Pradeep A, Sathyanarayana P, Green J
PLoS One. 2012; 7(7):e38530.
PMID: 22808010
PMC: 3396641.
DOI: 10.1371/journal.pone.0038530.